Main menu

Recent Pfizer Press Releases

8/14/14 5:01pm EDT
Pfizer Announces FDA Acceptance Of And Priority Review Designation For Biologics License Application For Investigational Meningococcal B Vaccine

Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bivalent recombinant LP2086 (rLP2086), the company’s vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 through 25 year olds. The FDA has also granted Priority Review designation for the BLA, providing an anticipated Prescription Drug User Fee Act (PDUFA) action date of February 14, 2015.

8/13/14 5:42pm EDT
Advisory Committee on Immunization Practices Votes to Recommend Pfizer’s Prevnar 13® Vaccine in Adults Aged 65 Years and Older

Pfizer Inc. (NYSE:PFE) today announced that the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein] (PCV13) for routine use to help protect adults aged 65 years and older against pneumococcal disease, which includes pneumonia caused by the 13 pneumococcal serotypes included in the vaccine. Specifically, the ACIP voted to recommend the following:

8/7/14 8:00am EDT
European Medicines Agency Accepts Application Seeking New Indication For Prevenar 13®1 For Prevention Of Pneumococcal Pneumonia In Adults

Application Includes Data from Pfizer’s Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)

Pfizer Inc. (NYSE:PFE) announced today that the European Medicines Agency (EMA) has accepted Pfizer’s application seeking to expand the indication for Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults to include the prevention of pneumonia caused by the 13 pneumococcal serotypes contained in the vaccine.

8/4/14 8:00am EDT
Rascal Flatts Joins the Thousands of People Who Choose Nexium® 24HR Every Day for Their Frequent Heartburn

Join Rascal Flatts Today and Choose Nexium 24HR - Satisfaction Guaranteed

Pfizer Inc. (NYSE:PFE) announced today that the members of Rascal Flatts, the most-awarded country music band of the past decade, are among the thousands of people who choose Nexium® 24HR every day since becoming available without a prescription for frequent heartburn this past May.

7/30/14 8:00am EDT
Pfizer Enters Into Agreement To Acquire Baxter’s Portfolio Of Marketed Vaccines

Pfizer Inc. today announced that it has entered into a definitive agreement to acquire Baxter International Inc.’s portfolio of marketed vaccines for $635 million.  As part of the transaction, Pfizer will also acquire a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured.  

7/29/14 7:00am EDT
European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE

  • In the AMPLIFY trial, Eliquis was shown to be non-inferior for the treatment of recurrent venous thromboembolism (VTE)/VTE-related death and was statistically superior in the primary safety endpoint of major bleeding vs. enoxaparin/warfarin
  • In the AMPLIFY-EXT trial, Eliquis demonstrated a superior reduction in VTE/all-cause death with no statistical difference in major bleeding events vs. placebo

7/29/14 7:00am EDT

  • Second-Quarter 2014 Reported Revenues(1) of $12.8 Billion
  • Second-Quarter 2014 Adjusted Diluted EPS(2) of $0.58, Reported Diluted EPS(1) of $0.45
  • Repurchased $2.9 Billion of Common Stock to Date in 2014
  • Reaffirmed 2014 Adjusted Diluted EPS(2) Guidance; Updated Certain Other 2014 Financial Guidance Components
  • Expects to Complete U.S. Regulatory Submission for Palbociclib in Advanced Breast Cancer in August 2014

7/17/14 8:06am EDT
Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to Assess Effectiveness and Safety of Eliquis® (apixaban) in Patients with NVAF Undergoing Cardioversion

Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced that the first patient has been enrolled into a Phase IV clinical trial called EMANATE (Eliquis evaluated in acute cardioversion coMpared to usuAl treatmeNts for AnTicoagulation in subjEcts with NVAF) assessing the effectiveness and safety of Eliquis in patients with nonvalvular atrial fibrillation (NVAF) undergoing cardioversion. Eliquis is currently approved to reduce the risk of stroke and systemic embolism in patients with NVAF.

7/16/14 10:00am EDT
#FOGO? – New Survey Reveals 87% of Americans have a Fear of Getting Old (FOGO) – Results Show Top Fear is Decline in Physical Ability1

Pfizer’s Get Old Campaign Challenges Conventional Attitudes about Aging

New social study finds 4.2 million tweets a year on aging; topic of health grew 48% in 2014 over 20132

Life expectancy continues to climb — up to more than 81 years for women and 76 years for men3 – but many of us have concerns around aging. Pfizer is challenging Americans to address their #FOGO – Fear of Getting Old – as the next phase of Get Old, an initiative by Pfizer around aging, encouraging honest conversations and celebrating getting “old” at whatever stage of life you are.

7/16/14 9:25am EDT
Pfizer to Acquire InnoPharma, Inc.

InnoPharma Has Established Track Record in the Development of Hard-to-Make, Differentiated, Sterile Injectable Products
Portfolio of 10 Approved Products and Pipeline of More Than 30 Products in Development; 19 Pending Approval with the United States Food and Drug Administration

Pfizer Inc. (NYSE:PFE) and InnoPharma, Inc., a privately held pharmaceutical development company, today announced that they have entered into an agreement under which Pfizer will acquire InnoPharma.

7/16/14 7:00am EDT
Pfizer Announces Positive Top-Line Results From Phase 3 Study Of NONACOG ALFA (BeneFIX®) Once-Weekly Prophylaxis For Hemophilia B

Once-Weekly Prophylaxis Treatment with BeneFIX® Significantly Reduced Annualized Bleeding Rate Compared to On-Demand Treatment

Pfizer Inc. (NYSE:PFE) today announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX® Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe hemophilia B. The top-line results of the study showed that the primary study endpoint was met and hemophilia B patients taking once-weekly BeneFIX (100 IU/Kg) showed a statistically significant reduction in the annualized bleeding rate (ABR) (P < 0.0001) relative to on-demand treatment with BeneFIX.

7/7/14 4:36pm EDT
CliniWorks Forms a Strategic Alliance with Pfizer to Develop a Population Health Management Platform with Advanced Analytics and Patient Care Capabilities

CliniWorks announced a strategic alliance between its Israeli subsidiary CliniWorks (Israel) Ltd. (“CliniWorks Israel”) and Pfizer Inc. (“Pfizer”) to jointly advance the parties’ respective capabilities in working with healthcare provider organizations to identify and close clinical or quality gaps to improve population health.

7/1/14 12:00pm EDT
Pfizer Inc. Receives Kosher Certification for Elelyso™ (taliglucerase alfa) for Injection, for the Treatment of Type 1 Gaucher Disease

Treatment for rare inherited lysosomal storage disorder is the first prescription medication to receive kosher certification from the Orthodox Union

Pfizer Inc. (NYSE:PFE) today announced that the Orthodox Union (OU) has granted kosher certification to ELELYSO™ (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of Type 1 Gaucher disease. ELELYSO is the first prescription medication to be certified kosher by the OU, a milestone for the brand which was approved by the U.S. Food and Drug Administration (FDA) in May 2012.

6/26/14 11:20am EDT
Pfizer Declares 26-Cent Third-Quarter 2014 Dividend

The board of directors of Pfizer Inc. today declared a 26-cent third-quarter 2014 dividend on the company’s common stock, payable September 3, 2014, to shareholders of record at the close of business on August 1, 2014.

6/26/14 9:45am EDT
James C. Smith Elected to Pfizer’s Board of Directors


Pfizer Inc. today announced the election of James C. Smith to its Board of Directors, effective immediately. Mr. Smith also was appointed to the Corporate Governance and Science and Technology Committees of Pfizer’s Board.

6/24/14 10:00am EDT
Pfizer Invites Public to View and Listen to Webcast of July 29 Conference Call with Analysts


Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 29, 2014. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2014 Performance Report, to be issued that morning.

6/20/14 9:54am EDT
Prevenar 13® Indication Extended in Japan


Adults 65 or older can now be immunized with the same Pneumococcal Conjugate Vaccine used in children.

6/18/14 5:01pm EDT
Two-Year Results From Pfizer’s XELJANZ® (Tofacitinib Citrate) ORAL Start Study Published in The New England Journal of Medicine


Phase 3 Study ORAL Start Showed XELJANZ Monotherapy Superior to Methotrexate in Inhibiting the Progression of Structural Damage and Reducing Signs and Symptoms of Rheumatoid Arthritis in Methotrexate-Naïve Patients

Findings Contribute to Growing Body of Evidence Supporting Efficacy and Safety Profile of XELJANZ as Monotherapy in Rheumatoid Arthritis

Pfizer Inc. (NYSE:PFE) announced today the publication of two-year results from the ORAL Start study in the June 19 issue of The New England Journal of Medicine.